Activation of PI3K/AKT/mTOR correlates with local recurrence and poor disease-free survival (DFS) in patients with early-stage NSCLC undergoing stereotactic body radiation therapy (SBRT) [76]. The gene discussed is MTOR; the disease is non-small cell lung carcinoma.